Search

Author/Creator de Pril, Veerle

1. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. Issue 2 (December 2015)

Authors:
Weber, Jeffrey; Grob, Jean-Jaques; Margolin, Kim; Ascierto, Paolo; Sznol, Mario; Ott, Patrick; Lejeune, Chantal; de Pril, Veerle; Ruisi, Mary; Hodi, F
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. (4th November 2015)

Authors:
Weber, Jeffrey; Grob, Jean-Jaques; Margolin, Kim A; Ascierto, Paolo A; Sznol, Mario; Ott, Patrick A; Lejeune, Chantal; de Pril, Veerle; Ruisi, Mary M; Hodi, F Stephen
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Issue 5 (May 2015)

Authors:
Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Konto, Cyril; Hoos, A...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 5(2015:May)
Page Start:
522
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Issue 11 (November 2020)

Authors:
Ascierto, Paolo A; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance, Ana M; Dalle, Stephane; Cowey, C Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Márquez-Rodas, Iván; Butler, Marcus O; Maio, Michele; Middleton, Mark R; de la Cruz-Merino, Luis; Arenberger, Petr;...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 11(2020)
Page Start:
1465
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Issue 3 (26th September 2022)

Authors:
Weber, Jeffrey S.; Schadendorf, Dirk; Del Vecchio, Michele; Larkin, James; Atkinson, Victoria; Schenker, Michael; Pigozzo, Jacopo; Gogas, Helen; Dalle, Stéphane; Meyer, Nicolas; Ascierto, Paolo A.; Sandhu, Shahneen; Eigentler, Thomas; Gutzmer, Ralf; Hassel, Jessica C.; Robert, Caroline; Carlino, ...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 3(2023)
Page Start:
517
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. Issue 12 (22nd October 2019)

Authors:
Yokota, Kenji; Uchi, Hiroshi; Uhara, Hisashi; Yoshikawa, Shusuke; Takenouchi, Tatsuya; Inozume, Takashi; Ozawa, Kentaro; Ihn, Hironobu; Fujisawa, Yasuhiro; Qureshi, Anila; de Pril, Veerle; Otsuka, Yasushi; Weber, Jeffrey; Yamazaki, Naoya
Journal:
Journal of dermatology
Issue:
Volume 46:Issue 12(2019)
Page Start:
1197
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Issue 3 (March 2017)

Authors:
Coens, Corneel; Suciu, Stefan; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Celeste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bottomley, Andre...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 3(2017:Mar.)
Page Start:
393
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗